6 BlackRock Palvella Therapeutics Trades
BlackRock's position in Palvella Therapeutics is currently worth $78.9M. That's 0.00% of their equity portfolio (2175th largest holding). The investor owns 5.62% of the outstanding Palvella Therapeutics stock. The stake costed the investor $33.9M, netting the investor a gain of 133% so far.
News about Palvella Therapeutics, Inc. and BlackRock
Pieris Pharmaceuticals Faces Agreement Termination and Pursues New Opportunities
The latest announcement is out from Pieris Pharmaceuticals (PIRS). Pieris Pharmaceuticals, Inc. has received a notice from Les Laboratoires Servier…
PIRS Stock Earnings: Pieris Pharmaceuticals Reported Results for Q1 2024
Pieris Pharmaceuticals (NASDAQ: PIRS ) just reported results for the first quarter of 2024. Pieris Pharmaceuticals reported earnings per share of -$3.95. The...
Pieris Pharmaceuticals OKs 1-for-80 reverse stock split
Pieris Pharmaceuticals (NASDAQ:PIRS) said Friday it has approved a 1-for-80 reverse stock split of the company''s common stock.The new CUSIP number following…
Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split
BOSTON, MA / ACCESSWIRE / April 19, 2024 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) today announced that its Board of Directors has approved a 1-for-80 rev...